trending Market Intelligence /marketintelligence/en/news-insights/trending/b2azmtibdnjmlvp4mqplwq2 content esgSubNav
In This List

Dimerix names 1st chief medical officer

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Dimerix names 1st chief medical officer

Dimerix Ltd. named David Packham to the newly created position of chief medical officer.

Packham was a principal investigator on Dimerix's phase 2a trial of DMX-200 in chronic kidney disease that successfully concluded in 2017, the company said.

Packham is also director of the Melbourne Renal Research Group, a specialist research facility for nephrology studies. He will lead Melbourne-based Dimerix's development efforts for DMX-200.